U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H44O12
Molecular Weight 584.6525
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OUABAIN

SMILES

C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=LPMXVESGRSUGHW-HBYQJFLCSA-N
InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1

HIDE SMILES / InChI

Molecular Formula C29H44O12
Molecular Weight 584.6525
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23761677 http://www.druginfosys.com/drug.aspx?drugcode=537&type=9

There is no available information about this compound

CNS Activity

Curator's Comment: SMALL doses of ouabain have powerful central nervous depressant effects. Ouabain directly stimulates the PNS center in the brain

Originator

Curator's Comment: Ouabain was discovered and so named in 1888 by Amaud

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P50993
Gene ID: 477.0
Gene Symbol: ATP1A2
Target Organism: Homo sapiens (Human)
41.0 nM [Ki]
Target ID: P13637
Gene ID: 478.0
Gene Symbol: ATP1A3
Target Organism: Homo sapiens (Human)
15.0 nM [Ki]
63.0 nM [IC50]
37.0 nM [IC50]
Target ID: P05023|||Q9UJ20
Gene ID: 476.0
Gene Symbol: ATP1A1
Target Organism: Homo sapiens (Human)
50.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Ouabain

Approved Use

Ouabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias.
Primary
Ouabain

Approved Use

Ouabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias.
Primary
Ouabain

Approved Use

Ouabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias.
PubMed

PubMed

TitleDatePubMed
Ouabain-induced ventricular tachycardia and its effect on the performance and metabolism of the dog heart.
1959 Sep
The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.
1968 Sep
Antiarrhythmic and antifibrillatory properties of aprindine.
1975 Aug
[Inhibitory effect of taurine on ouabain-induced arrythmia].
1975 Jan
The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
1975 Jan-Feb
[Glycogen content in rat brain in ouabain encephalopathy].
1975 Jan-Mar
[Pharmacological studies of celiprolol: III. Effects of celiprolol on the cardiovascular system and renal function, and its antiarrhythmic effects].
1990 Apr
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
1991 Jan-Feb
Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats.
1992
Neuronal Fos-like immunoreactivity in ouabain-induced hypertension.
2000 Sep 8
Activation of Na+/K+-ATPase by the serum and glucocorticoid-dependent kinase isoforms.
2002
The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules.
2004 Aug
Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain.
2004 Nov
[Renal sodium handling in ouabain-hypertensive rats].
2005 Aug
The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro.
2005 Feb
[Comparative study of properties of Na+, K+-ATPase and Mg2+-ATPase of the myometrium plasma membrane].
2005 Mar-Apr
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.
2008 Aug
Ouabain treatment changes the role of endothelial factors in rat resistance arteries.
2008 Dec 14
ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit.
2008 Jul
Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation.
2008 Jun
Structural and functional characteristic of a model for deep-seated lacunar infarct in rats.
2008 Oct 15
Response of sodium pump to ouabain challenge in human glioblastoma cells in culture.
2009
Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat.
2009 Jan
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells.
2009 Nov 1
The new targets of ouabain in retinal interneurons of Sprague-Dawley rats.
2010 Apr 5
Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain.
2010 Feb
DNA damage after intracerebroventricular injection of ouabain in rats.
2010 Feb 26
Upregulation of Na+ and Ca2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats.
2010 Jan
Effects of long-term ouabain treatment on blood pressure, sodium excretion, and renal dopamine D(1) receptor levels in rats.
2010 Jan
Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes.
2010 Jan 1
Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
2010 Jul 1
Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain.
2010 Jun
Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain.
2010 May
Patents

Sample Use Guides

0.004 mg/kg - IV, as Recommended Initial dose 24 mg 24 hourly PO, as Maintenance dose
Route of Administration: Other
Ouabain (0.1 uM-1.0 uM) inhibits the Na+ pump and increases stored Ca2+ in cultured rat astrocytes.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:21:16 GMT 2025
Edited
by admin
on Mon Mar 31 18:21:16 GMT 2025
Record UNII
5ACL011P69
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OUABAIN
EP   MART.   MI   WHO-DD  
Common Name English
G-STROPHANTHIN
JAN   MI  
Preferred Name English
Ouabain [WHO-DD]
Common Name English
(1.BETA.,3.BETA.,5.BETA.,11.ALPHA.)-3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-1,5,11,14,19-PENTAHYDROXYCARD-20(22)-ENOLIDE
Common Name English
NSC-25485
Code English
G-STROPHANTHIN [MI]
Common Name English
OUABAIN ANHYDROUS [HSDB]
Common Name English
CARD-20(22)-ENOLIDE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-1,5,11,14,19-PENTAHYDROXY-, (1.BETA.,3.BETA.,5.BETA.,11.ALPHA.)-
Common Name English
ACOCANTHERIN
Common Name English
OUABAIN [MI]
Common Name English
OUABAIN [EP MONOGRAPH]
Common Name English
STROPHANTIN-G
Common Name English
OUABAIN [MART.]
Common Name English
GRATUS STROPHANTHIN
Common Name English
G-STROPHANTHIN [JAN]
Common Name English
Classification Tree Code System Code
WHO-ATC C01AC01
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
WHO-VATC QC01AC01
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
Code System Code Type Description
MESH
D010042
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
CHEBI
472805
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
ECHA (EC/EINECS)
211-139-3
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
SMS_ID
100000076204
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
FDA UNII
5ACL011P69
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
HSDB
3519
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL222863
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
PUBCHEM
439501
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
DRUG CENTRAL
2004
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
IUPHAR
4826
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
EVMPD
SUB14721MIG
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
RXCUI
7762
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
OUABAIN
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
DRUG BANK
DB01092
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
MERCK INDEX
m8270
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY Merck Index
CHEBI
145798
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
NSC
25485
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID0043765
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
CAS
630-60-4
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY
MERCK INDEX
m10252
Created by admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SOLVATE->ANHYDROUS
TRANSPORTER -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY